Abstract. The products of the E-cadherin (CDH1), H-cadherin (CDH13) and a disintegrin and metalloproteinase with thrombospondin motif 18 (ADAMTS18) genes are proteins displaying structural features and functions on the cell surface membrane, and have been reported to be involved in cancer progression. Using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and methylation-specific PCR (MSP) analysis, the promoter methylation status and messenger RNA (mRNA) expression levels of CDH1, CDH13 and ADAMTS18, which are putative tumor-suppressor genes located on chromosome 16q, were evaluated. In addition, the mRNA expression levels of DNA methyltransferases (DNMTs) 1, 3A and 3B were examined, and the correlations among the different parameters analyzed were studied in 36 lymphomas and 16 non-malignant lymphoid tissue samples. A significant positive correlation was identified between the expression levels of CDH1 and CDH13 (r=0.735, P<0.01). ADAMTS18 expression also exhibited a significant positive correlation with both CDH1 and CDH13 mRNA expression levels (r=0. 625, P<0.01; and r=0.720, P<0.01, respectively). Our results indicated that CDH1, CDH13 and ADAMTS18, which are localized on chromosome 16q, are remarkably correlated and frequently methylated in human lymphomas, and their methylation could not be explained solely by the mRNA expression level of DNMTs.
Introduction
Aberrant promoter hypermethylation contributes to the transcriptional inactivation of a number of genes in various malignant diseases (1) . However, the precise mechanisms underlying this aberration remain unclear. DNA methylation is established by the catalytic activity of a family of DNA methytransferases (DNMTs), which includes DNMT1, DNMT3A and DNMT3B (2) . The association between DNMTs expression and promoter hypermethylation of the tumor-suppressor gene (TSG) P15
INA4B has been reported in acute myeloid leukemia (3) . In another study on diffuse large B-cell lymphoma (DLBCL), the overexpression of DNMT3B and DNMT1 proteins was significantly correlated with the promoter hypermethylation of various genes, including p16 and von Hippel-Lindau (4). However, a lack of association between deregulated DNMTs expression and aberrant promoter methylation has also been reported (5) (6) (7) (8) .
E-cadherin, the gene product of CDH1, is a calciumdependent cell adhesion molecule that is essential for maintaining the integrity of cell-cell adhesions (9) . Downregulation of E-cadherin has been identified in numerous human cancers, and a loss of E-cadherin function was demonstrated to be associated with CDH1 promoter hypermethylation and increased invasiveness and metastasis in human tumors (9, 10) . However, in another study on DLBCL, CDH1 promoter hypermethylation was observed not to be correlated with the expression levels of DNMTs (4) .
H-cadherin, the gene product of CDH13, is a novel member of the cadherin family (11) . H-cadherin has a unique feature, in that it is devoid of a transmembrane domain, and is anchored to the cell surface membrane via a glycosylphosphatidylinositol (GPI) moiety instead. In addition, it also lacks a cytoplasmic domain (11) . CDH13 downregulation has been associated with the tumorigenesis of multiple cancers (11) . CDH13 silencing due to promoter hypermethylation and/or loss of heterozygosity is associated with tumor progression in BCLs (12) .
A disintegrin and metalloproteinase with thrombospondin motif 18 (ADAMTS18) belongs to the ADAMTSs family, a group of secreted proteases that control several cell functions (13). Porter et al (14) demonstrated that there was a downregulation of several members of the ADAMTS family, including ADAMTS18, in human breast cancer compared with non-neoplastic mammary tissues. In addition, silencing of ADAMTS18 by methylation of promoter CpG islands has been reported in multiple carcinoma cell lines, particularly in cell lines derived from esophageal and nasopharyngeal carcinomas (15) .
Tumor cells are characterized by frequent deletions of chromosomal regions that encode multiple TSGs (16) . CDH1, CDH13 and ADAMTS18 are all located on chromosome 16q (16q22.1, 16q24.2 and 16q23.1, respectively). Similar to epigenetic modifications, genetic changes that are caused mainly by chromosomal loss of heterozygosity or mutations within the genes have been demonstrated to be associated with the upregulation of oncogenes or the downregulation of TSGs (16, 17) .
To the best of our knowledge, the correlations among the expression levels of CDH1, CDH13, ADAMTS18 and DNMTs, as well as their associations with the promoter methylation status of CDH1, CDH1 and ADAMTS18 in human lymphoma, have not been analyzed to date. Therefore, in the present study, the expression levels of CDH1, CDH13 and ADAMTS18 were investigated by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in human lymphoma. In addition, the frequency of methylation of the CDH1, CDH13 and ADAMTS18 gene promoters was examined using methylation-specific PCR (MSP). It was observed that these chromosome 16-located TSGs are frequently methylated and correlated, but they are not associated with the DNMTs levels in human BCL.
Patients and methods
Patients. From the files of the Department of Hematology of Gunma University Hospital (Gunma, Japan), cases of surgically biopsied lymph nodes from patients that were collected between December 2006 and July 2012 were obtained upon receiving appropriate institutional review board approval from Gunma University and patients' written informed consent. For all cases, the diagnosis was based on a morphological and immunohistochemical analysis according to the World Health Organization classification (18) . The criterion for the selection of these cases was the availability of fresh-frozen optimal cutting temperature compound-embedded tumor biopsy specimens collected prior to any treatment. The present study included 29 cases of DLBCL, 7 cases of mantle cell lymphoma and 16 samples of non-malignant lymphoid tissues (including necrotizing lymphadenitis, reactive lymph nodes, immunoglobulin G4-associated diseases, follicular hyperplasia and granulomatous lymphadenitis).
Purification of genomic DNA (gDNA) and total RNA. gDNA and total RNA were purified from each tumor tissue using the AllPrep DNA/RNA Mini kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's protocol.
RT-qPCR. Total RNA (≤1 µg) for qPCR assays was treated and reverse transcribed using PrimeScript RT Reagent kit with gDNA Eraser (Takara Biotechnology Co., Ltd., Dalian, China) according to the protocol provided by the manufacturer. RT-qPCR was performed using SYBR Green PCR Master Mix (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA) on a 7300 Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.). Complementary DNA (1 µl) was mixed with gene-specific primers (listed in Table I ), along with SYBR Green PCR Master Mix in a final volume of 20 µl. PCR was performed under the following conditions:
Initial denaturation at 95˚C for 10 min, followed by 45 cycles of denaturation at 95˚C for 15 sec and annealing/extension at 60˚C for 1 min. The relative level of expression of DNMTs, CDH1, CDH13 and ADAMTS18 were normalized using a reference gene (β-actin) and control cells (HL60), and calculations were performed using the 2 -∆∆Cq method (19) .
Bisulfite modification and MSP. The extracted DNA was modified using the Methyl Easy Xceed Rapid DNA Bisulphite Modification kit (Genetic Signatures, Darlinghurst, Australia) according to the manufacturer's protocol. MSP was performed in a total volume of 20 µl, containing 2 µl sodium bisulfitemodified template DNA, using EpiTaq HS for bisulfite-treated DNA (Takara Biotechnology Co., Ltd.). Each MSP reaction was performed with the following conditions: Denaturation at 95˚C for 5 min, followed by 40 cycles of denaturation at 95˚C for 30 sec, 30 sec at the specific annealing temperature for CDH1 and CDH13 [53˚C for methylated (M) and 57˚C for unmethylated (U) DNA] and ADAMTS18 (57˚C for M and U DNA) and extension at 72˚C for 30 sec, followed by a final 4-min extension at 72˚C. The primer sequences were as follows: CDH1 (CDH1UM sense, 5'-GGT TTG ATT TGA TTG TATTT-3' and CDH1UM antisense, 5'-AAA TAC ATC CCT CAC AAAT-3'; and CDH1M sense, 5'-GGT TCG ATT CGA TCG TATTC-3' and CDH1M antisense, 5'-GAA TAC GTC CCT CGC AAAT-3'); CDH13 (CDH13UM sense, 5'-TTG TGG GGT TGT TTT TTGT-3' and CDH13UM antisense, 5'-AAC TTT TCA TTC ATA CAC ACA-3'; and CDH13M sense, 5'-TCG CGG GGT TCG TTT TTCGC-3' and CDH13M antisense, 5'-GAC GTT TTC ATT CAT ACA CGCG-3'); and ADAMTS18 (ADAMTS18UM sense, 5'-AAA TTG TAG TTT GGT AGG TTT GT-3' and ADAMTS18UM antisense, 5'-CAA CTC CAA ATA AAA ACC ACCA-3'; and ADAMTS18M sense, 5'-TTG TAT TCG GTA GGT TCGC-3' and ADAMTS18M antisense, 5'-ACT CCA AAT AAA AAC CGC CG-3'). Primer sequences were described previously (15, 20, 21) and were purchased from Eurofins MWG Operon, Inc. (Huntsville, AL, USA). MSP products were visualized under ultraviolet illumination following electrophoresis in 2% agarose gels containing GelRed nucleic acid gel stain (Biotium, Fremont, CA, USA). (22) (Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan), CTB-1 (23) and SLVL (24) (Riken, Saitama, Japan)] and one patient primary DLBCL cell line were cultured in RPMI-1640 medium (Wako Pure Chemical Industries, Ltd., Osaka, Japan) at 37˚C in an atmosphere of 5% CO 2 and treated with the demethylating agent 5-aza-dC (Wako Pure Chemical Industries, Ltd.). Cells (5x10 4 ) were grown in the absence or presence of 5-aza-dC at a concentration of 3 µM. The demethylation treatment was performed three times to verify the results.
5-Aza-2'-deoxycytidine (5-aza-dC) treatment. Established lymphoma cell lines [Raji
Statistical analysis. Using the SPSS 20 software (IBM SPSS, Armonk, NY, USA), differences in the mean rank values between groups were analyzed with the Mann-Whitney U test. The significance of associations between parameters were analyzed by Spearman's correlation coefficient. P<0.05 was considered to indicate a statistically significant difference.
Results

Expression of DNMTs, CDH1, CDH13 and ADAMTS18.
The relative mRNA expression levels of DNMT1, DNMT3A, DNMT3B, CDH1, CDH13 and ADAMTS18 were detected by RT-qPCR in 36 cases of lymphoma and in 16 samples of non-malignant lymphoid tissue. The mean rank expression levels of DNMTs (1, 3A and 3B) in the lymphomas were significantly higher (P=0.044, P=0.036 and P=0.013) than those in the non-malignant tissues by 45.4, 45.9 and 60.4%, respectively Primers were purchased from Takara Biotechnology Co., Ltd. and designed using One Step PrimeScript™ RT-PCR kit (Perfect Real Time), which is an online support system to search for optimized primers when using SYBR ® Green I detection in RT-qPCR. DNMT, DNA methyltransferase; CDH1, E-cadherin; CDH13, H-cadherin; ADAMTS18, a disintegrin and metalloproteinase with thrombospondin motifs 18; RT-qPCR, reverse transcription-quantitative polymerase chain reaction. ( Fig. 1A-C) . The expression of CDH1 and ADAMTS18 were both significantly (P<0.01) reduced in lymphomas by 36.0% with respect to non-malignant tissues, while CDH13 expression was non-significantly reduced by 14.4% in lymphomas compared with non-malignant tissues (Fig. 1D-F) . The expression of CDH1 and ADAMTS18 was significantly (P=0.008 and P=0.019, respectively) reduced in samples with a hypermethylated promoter compared with those with an unmethylated promoter, while CDH13 expression displayed a non-significant reduction (17.9%) in subjects with a methylated CDH13 promoter (Fig. 3A) . No associations were identified between the increased levels of DNMTs mRNA and the CDH1, CDH13 or ADAMTS18 promoter hypermethylation ( Fig. 3B-D) . To confirm that promoter methylation was responsible for the silencing of CDH1, CDH13 and ADAMTS18 expression, methylated lymphoma cell lines were treated with 5-aza-dC, a demethylating agent, and CDH1, CDH13 and ADAMTS18 expression was examined by RT-qPCR. Upon treatment with 5-aza-dC, the promoter region of the CDH1, CDH13 and ADAMTS18 genes exhibited hypomethylation, and their mRNA expression levels were increased (Fig. 4) .
Associations between the relative mRNA expression levels of CDH1, CDH13 and ADAMTS18.
The correlations between the different tested parameters were evaluated across the spectrum of both lymphoma and non-malignant tissues. The CDH1 expression level exhibited a significantly positive correlation with the CDH13 expression level (r=0.735, P<0.01) (Fig. 5A) . Furthermore, the ADAMTS18 expression level was positively correlated with the CDH1 and CDH13 expression levels (r=0.625, P<0.01; and r=0.720, P<0.01, respectively) (Figs. 5B and C).
Discussion
Promoter hypermethylation and loss of function of CDH1, CDH13 and ADAMTS18 have been reported in various cancers and cancer cell lines (10, 11, 13) . In the present study, the promoter methylation of CDH1, CDH13 and ADAMTS18, which are putative TSGs located on chromosome 16q (16q22.1, 16q24.2 and 16q23.1, respectively), was investigated using MSP, and the expression levels of DNMTs, CDH1, CDH13 and ADAMTS18 were examined using RT-qPCR to study whether these parameters are correlated and associated with DNMTs in human BCL.
Methylation of the CDH1 promoter CpG islands and consequent loss of E-cadherin expression has been reported in multiple tumor tissues (25) (26) (27) (28) (29) (30) (31) . ADAMTS18 has been reported to be downregulated through promoter methylation in esophageal and nasopharyngeal cancer cell lines (15) . In the present study, the relative mRNA expression levels of CDH1 and ADAMTS18 were both significantly reduced in lymphoma samples by 36.0% with respect to non-malignant tissues. In addition, promoter hypermethylation of CDH1 and ADAMTS18 was detected in 31/36 (86.1%) and 28/36 (77.8%) of lymphomas, respectively. Furthermore, the reduction of CDH1 and ADAMTS18 was significantly associated with their corresponding hypermethylated promoters when compared with their unmethylated promoters. Therefore, the current results suggest that the aberrant expression of CDH1 and ADAMTS18 and their promoter hypermethylation may be important in lymphomagenesis.
CDH13 downregulation due to promoter hypermethylation has been observed in various cancers (11), including Figure 2 . Methylation-specific PCR. The DNA methylation status of CDH1, CDH13 and ADAMTS18 was assessed for selected lymphoma and non-malignant samples that were amplified by PCR with primers specific for the U or M CpG islands of the target genes upon modification with sodium bisulfite. PCR, polymerase chain reaction; CDH1, E-cadherin; CDH13, H-cadherin; ADAMTS18, a disintegrin and metalloproteinase with thrombospondin motifs 18; M, methylated; U, unmethylated.
BCLs (12) . In the present study, the relative mRNA expression level of CDH13 in human lymphomas was reduced by 14.4% (not significant) compared with that in non-malignant tissues. Furthermore, methylation of CDH13 was detected more frequently in lymphoma (91.7%) than in non-malignant tissues (50.0%), and there was a non-significant reduction in CDH13 expression in subjects with a methylated CDH13 promoter (17.9%). No significant differences were observed among the expression levels of DNMTs in subjects with a methylated CDH13 promoter compared with those with unmethylated promoters. These non-significant results may be due to the fact that human clinical samples are heterogeneous, with cytological diversity and different variants that may neutralize the aberrant expression of genes. Genes with transcriptional inactivation due to methylation are sensitive to DNA methylation inhibitors and can easily be reactivated (32) . The methylation inhibitor 5-aza-dC, can be incorporated during DNA synthesis, and reduces the capacity for DNA methylation by DNMTs, thus reversing the methylation status of the promoters of genes (32, 33) . In the present study, methylated BCL cell lines (Raji, CTB-1, SLVL) and a primary patient cell line were treated with 5-aza-dC. Following demethylation treatment, the expression levels of CDH1, CDH13 and ADAMTS18 mRNA were upregulated ≥2-fold, with corresponding complete or partial promoter hypomethylation.
By contrast, in the current surgically-resected tumor samples, not apparent significant correlation was identified between the methylation status of TSGs and the expression levels of DNMTs. These findings are in agreement with previous studies that failed to demonstrate any significant correlation between DNMTs expression and aberrant promoter methylation of the tested genes (5, 6, 34, 35) . This finding can be explained by the fact that the overexpression of DNMTs is considered to be the primary mechanism responsible for the hypermethylation of TSGs in cancer cells, while a gain of methylation could also be secondary to the overexpression of transcriptional repressors or to the loss of transcriptional activators, as well as the result of an interallelic transfer of methylation via gene pairing (6, 36) . Another study (8) revealed that transgenic overexpression or complete depletion of DNMT3B did not affect the methylation status of HCT-116 colon cancer cells. Furthermore, in the present study, the expression levels of DNMTs mRNAs were significantly higher in lymphomas than in non-malignant tissue samples. This may be attributable to differences in the cell proliferation rate between lymphomas and non-malignant tissues (6) . Taken together, since tumor cell lines are developed from single cells, and therefore consist of cells with a uniform genetic composition, it is logical that the expression of genes displayed a clearer association with their corresponding promoter's methylation status than with that observed in the heterogeneous tumor clinical samples. CDH1 and CDH13 are important cell adhesion molecules, and alterations in their structure and function often cause a reduction in the adhesion between tumor cells, which may cause the detachment of cells from the primary tumors and the acquisition of invasive and metastatic properties (10, 11) . Notably, in the present study, a significant positive correlation between the expression levels of both CDH1 and CDH13 was observed. Regulation of VE-cadherin by N-cadherin was previously described in non-malignant human umbilical vein endothelial cells (37) . It has also been demonstrated that N-cadherin and VE-cadherin are co-expressed in human breast cancer (38) . N-cadherin controls the expression of VE-cadherin, and the latter regulates the subcellular localization of N-cadherin by causing its translocation from the cell surface (38) . Since CDH13 lacks the transmembrane and cytoplasmic regions of other cadherins, and instead uses a GPI anchor and the interactions with specific ligands (11), we suggest that CDH1 may interact with CDH13 and facilitate its signaling inside the cell.
In addition, the present study identified significant positive correlations between the expression level of ADAMTS18 and the expression levels of CDH1 and CDH13. ADAMTSs, including ADAMTS18, are important in mediating the degradation of extracellular matrix proteins, as well as the ectodomain shedding of growth factors, growth factor receptors and adhesion molecules (13) . Interactions between metalloproteinases and adhesion molecules have been reported (10, 39, 40) . For example, Maretzky et al (39) demonstrated that ADAM10 contributes to E-cadherin shedding and to cell proliferation by modulating β-catenin signaling through E-cadherin shedding. Furthermore, ADAM15 catalyzes soluble E-cadherin shedding, which in turn leads to its binding to the ErbB receptor and to the stimulation of ErbB receptor signaling via human epidermal growth factor (HER) 2 and HER3 in breast cancer cells (40) . Therefore, the positive correlations between ADAMTS18 and CDH1 and CDH13 mRNA in the current study may reflect the requirement of ADAMTS for cadherin processing in the cells, and also suggest the existence of a common factor regulating these genes, which are all located on chromosome 16q, thus further emphasizing the importance of this region.
Of note, as presented in Fig. 5B and C, the expression of ADAMTS18 in replicate samples (16/52 samples, 30.8%) did not display any correlation with the expression of either CDH1 or CDH13. The complete lack of ADAMTS18 expression and the absence of correlation with CDH1, CDH13 or DNMTs in these patients' samples may imply that there is a loss of the ADAMTS18 gene locus.
Furthermore, to support our hypothesis that chromosome 16 and cell surface membrane-located TSGs are correlated with each other in human BCL, the present study examined the expression of another TSG located on the same chromosome, cyclin-dependent kinase inhibitor (CDKN) 2A (p16). It was observed that the expression levels of our tested TSGs did not exhibit any correlation with the CDKN2A expression level (data not shown).
In conclusion, our findings demonstrated that the expression levels of TSGs adjacently located at chromosome 16q (CDH1, CDH13 and ADAMT18) are positively correlated and frequently methylated, and that their methylation status is not associated with the expression levels of DNMTs in human lymphoma. Our findings suggest that aberrantly methylated cell surface membrane TSGs located on chromosome 16q are correlated and may be important role in the pathogenesis of human BCL.
